Fisher & Paykel Healthcare Corporation Limited (FPH.NZ)
- Previous Close
35.84 - Open
35.88 - Bid 35.33 x 485800
- Ask 35.80 x 241000
- Day's Range
35.32 - 36.50 - 52 Week Range
27.51 - 39.50 - Volume
363,317 - Avg. Volume
579,211 - Market Cap (intraday)
21.011B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
153.70 - EPS (TTM)
0.23 - Earnings Date May 28, 2025
- Forward Dividend & Yield 0.37 (1.05%)
- Ex-Dividend Date Dec 5, 2024
- 1y Target Est
34.67
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, it provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
www.fphcare.comRecent News: FPH.NZ
View MorePerformance Overview: FPH.NZ
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FPH.NZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FPH.NZ
View MoreValuation Measures
Market Cap
21.01B
Enterprise Value
21.04B
Trailing P/E
158.58
Forward P/E
50.76
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.96
Price/Book (mrq)
10.89
Enterprise Value/Revenue
11.97
Enterprise Value/EBITDA
57.15
Financial Highlights
Profitability and Income Statement
Profit Margin
9.44%
Return on Assets (ttm)
10.85%
Return on Equity (ttm)
9.70%
Revenue (ttm)
1.89B
Net Income Avi to Common (ttm)
178.5M
Diluted EPS (ttm)
0.23
Balance Sheet and Cash Flow
Total Cash (mrq)
116.6M
Total Debt/Equity (mrq)
7.82%
Levered Free Cash Flow (ttm)
303.21M